The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during ‘titration phase’ in patients with cancer pain

Abstract

Adequate and rapid pain control is one of the main goals of cancer pain treatment. The objective of this study was to assess the effect and tolerability of oral normal-release morphine during the initial phase of treatment in patients with moderate-to-severe cancer pain. Consecutive patients naïve to strong opioids received normal-release morphine 5 or 10 mg every 4 h during the titration phase (first 5 days), depending on previous analgesic therapy. Pain intensity was assessed using an 11-point Numerical Rating Scale (0–10), and data were recorded in a patient-compiled diary. The primary endpoint was the proportion of time with pain control (a reduction of at least 50% with respect to the baseline pain score) during the titration phase. A total of 159 consecutive patients (102 men; mean age 65 years) with cancer-related pain were enrolled. Pain control was observed for 75% (95% CI 70–80) of the follow-up period in the intent-to-treat population. Overall, 50% and 75% of patients achieved pain control within 8 and 24 h after starting normal-release morphine therapy respectively. The mean pain score was 7.63 points at baseline, and decreased to 2.43 and 1.67 points (both P < 0.001) at days 3 and 5 respectively. The most commonly reported adverse events were somnolence (24% of patients), constipation (22%), vomiting (13%), nausea (10%) and confusion (7%). Normal-release morphine results in rapid and satisfactory pain control, and is well tolerated, during the strong-opioid titration phase in patients with moderate-to-severe cancer pain.

Keywords

cancer pain morphine normal release oral tolerability

Get full access to this article

View all access options for this article.

References

1 Hanks G Cherny NI Fallon M . Opioid analgesic therapy. In: D Doyle G Hanks NI Cherny , (eds), Oxford textbook of palliative medicine, 3rd ed. Oxford : Oxford University Press ; 2004. p. 316–341.

2 World Health Organization . Cancer pain relief. Geneva : World Health Organization ; 1986.

3 World Health Organization . Cancer pain relief, 2nd ed. Geneva : World Health Organization ; 1996.

5 Hanks GW DeConno F Ripamonti C Ventafridda V Hanna M McQuay HJ Mercadante L . Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823 – 826 .

6 Hanks GW DeConno F Cherny N Hanna M Kalso E McQuay HJ Mercadante L . Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 2001; 84: 587 – 593 .

9 Mercadante S Radbruch L Caraceni A Cherney N Kaasa S Nauch F . Episodic (Breakthrough) pain. Consensus Conference of an Expert Working Group of the European Association for Palliative Care. Cancer 2002; 94: 832 – 839 .

10.

11.

11 Joint Formulary Committee . British National Formulary, 53rd ed. London : British Medical Association and Royal Pharmaceutical Society of Great Britain ; 2007.

12.

12 Regnard CF Badger C . Opioids, sleep and the time of death. Palliat Med 1987; 1: 107 – 110 .

13.

13 Klepstad P Kaasa S Cherny N Hanks GW De Conno F , Research Steering Comimitee of EAPC . Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005; 19: 477 – 484 .

14.

14 De Conno F Ripamonti C Brunelli C . Opioid purchases and expenditure in nine western European countries. “Are we killing off morphine? ”. Palliat Med 2005; 19: 179 – 184 .

15.

15 Chinellato A Terrazzani G Walley T Giusti P . Opioids in Italy: is marketing more powerful than the law? Lancet 2003; 362: 78 .

16.

16 Ripamonti C Fagnoni E Campa T Brunelli C De Conno F . Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006; 14: 400 – 407 .

17.

18.

18 Mattews JNS Altman DG Campbell MJ Royston P . Analysis of serial measurements in medical research. BMJ 1990; 300: 230 – 235 .

19.

19 Sawe J Dahlstrom B Paalzow L Rane A . Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629 – 635 .

20.

20 Hoskin PJ Hanks GW Aherne GW Chapman D Littleton P Filshie J . The bioavailability of and pharmacokinetics of morphine after intravenous, oral and buccal administration in health volunteers. Br J Clin Pharmacol 1989; 27: 499 – 505 .

21.

21 Gourlay GK Plummer JL Cherry DA Purser T . The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions. J Pain Symptom Manage 1991; 6: 431 – 436 .

22.

22 Cherny N Ripamonti C Pereira J Davis C Fallon M McQuay H . Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542 – 2554 .

23.

23 Grond S Zech D Diefenbach C Radbruch L Lehmann KA . Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 1996; 64: 107 – 114 .

24.

24 Caraceni A Portenoy RK . An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82: 263 – 274 .

25.

25 Ashby MA Fleming BG Brooksbank M Rounsefell B Runciman WB Jackson K . Description of a mechanistic approach to pain management in advanced cancer. Preliminary report. Pain 1992; 51: 153 – 161 .

26.

26 Zeppetella G O'Doherty CA Collins S . Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2001; 21: 87 – 92 .

27.

27 Swanwick M Haworth M Lennard RF . The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 2001; 15: 9 – 18 .

28.

28 Fortner BV Okon TA Portenoy RK . A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002; 3: 38 – 44 .

29.

29 Hwang SS Chang VT Kasimis B . Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003; 101: 55 – 64 .

30.

30 Banning A Sjørgen P Henriksen H . Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991; 45: 45 – 48 .

31.

31 Portenoy RK Hagen NA . Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273 – 281 .

32.

32 Fine PG Busch MA . Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998; 16: 179 – 183 .

33.

33 Zenz M Willweber-Strumpf A . Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075 – 1076 .